Radiotherapy-Induced Oral Mucositis Market Set for Strong Growth Through 2036, Driven by Emerging Therapies and Rising Cancer Burden | DelveInsight

The radiotherapy-induced oral mucositis market is expected to witness significant growth due to the increasing incidence of head and neck cancers and the expanding use of radiotherapy as a standard treatment modality. Rising awareness of supportive cancer care, coupled with the substantial unmet need for effective preventive and therapeutic options, is driving research and development activities in this field. The advancement of novel therapies, including Dusquetide (SGX942) (Soligenix), RRx-001 (EpicentRx), MIT-001 (MitoImmune Therapeutics), and others, is expected to improve treatment outcomes and expand market opportunities.

LAS VEGAS, Aug. 20, 2026 /PRNewswire/ -- Recently published Radiotherapy Induced Oral Mucositis Market Insights report includes a comprehensive understanding of current treatment practices, radiotherapy-induced oral mucositis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Radiotherapy Induced Oral Mucositis Market Summary

• The total radiotherapy-induced oral mucositis treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest radiotherapy-induced oral mucositis treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The prevalent cases of RIOM are expected to increase during the forecast period, driven by the growing use of radiotherapy in cancer treatment, rising incidence of head and neck cancers, an aging population, and improved access to oncologic care.
• Leading radiotherapy-induced oral mucositis companies, such as Soligenix, EpicentRx, MitoImmune Therapeutics, and others, are developing new radiotherapy-induced oral mucositis treatment drugs that can be available in the radiotherapy-induced oral mucositis market in the coming years. 
• The promising radiotherapy-induced oral mucositis therapies in clinical trials include Dusquetide (SGX942), RRx-001, MIT-001, and others.

Discover new treatment options for radiotherapy-induced oral mucositis @ https://www.delveinsight.com/report-store/radiotherapy-induced-oral-mucositis-market

Key Factors Driving the Growth of the Radiotherapy Induced Oral Mucositis Market 

• Increasing Incidence of Head and Neck Cancers: The rising global burden of head and neck cancers is increasing the number of patients receiving radiotherapy, a major cause of oral mucositis. As more patients undergo radiation-based treatment, the demand for effective prevention and management of RIOM continues to grow.
• Growing Adoption of Radiotherapy as a Standard Cancer Treatment: Radiotherapy remains a cornerstone in the treatment of many solid tumors, either as a standalone therapy or in combination with chemotherapy and immunotherapy. The expanding use of advanced radiation techniques is driving a larger patient pool at risk of RIOM, creating sustained market demand.
• Launch of RIOM Drugs: The dynamics of the RIOM market are expected to change in the coming years due to the launch of emerging therapies such as Dusquetide (SGX942) (Soligenix), RRx-001 (EpicentRx), MIT-001 (MitoImmune Therapeutics), and others.

According to Sharad Chandra Vinayak, Assistant Project Manager of Forecasting & Analytics at DelveInsight, advancements in immunomodulatory, anti-inflammatory, antioxidant, and regenerative therapies such as Dusquetide, RRx-001, and MIT-001 offer the potential to transform RIOM management by addressing the biological mechanisms driving mucosal injury and healing.

Radiotherapy Induced Oral Mucositis Market Analysis

• Management of radiation-induced oral mucositis is currently centered on supportive care and symptom relief rather than disease-specific treatment. 
• Standard interventions include comprehensive oral care protocols, saline and sodium bicarbonate mouth rinses, benzydamine mouthwash, topical anesthetics, systemic pain medications, and nutritional support to minimize mucosal injury and enhance patient comfort throughout cancer therapy. 
• Despite these measures, no therapies have been specifically approved for RIOM, underscoring a considerable unmet clinical need and providing opportunities for novel treatments designed to target the biological processes involved in mucosal damage and healing.
• RIOM is associated with substantial clinical complications, frequently resulting in hospitalization or extended hospital stays for nutritional supplementation, intravenous pain management, and antibiotic administration. In advanced cases, patients may experience severe difficulty with oral intake, requiring feeding tube placement and comprehensive supportive care.
• Several standardized tools are available to evaluate the severity of RIOM, including the World Health Organization (WHO) Oral Toxicity Scale, the National Cancer Institute (NCI) criteria, the Radiation Therapy Oncology Group (RTOG) grading system, and the Oral Mucositis Assessment Scale (OMAS). These assessment frameworks facilitate consistent disease evaluation, treatment monitoring, clinical trial outcomes, and standardized patient care across different healthcare settings.
• The therapeutic pipeline for RIOM remains relatively sparse, with only a limited number of investigational agents under development, such as Dusquetide (SGX942), RRx-001, and MIT-001. 
• These pipeline candidates are designed to target the inflammatory pathways and tissue injury associated with RIOM, highlighting ongoing efforts to introduce mechanism-based therapies that address the underlying causes of the disease.

Radiotherapy Induced Oral Mucositis Competitive Landscape

Some of the RIOM drugs under development include Dusquetide (SGX942) (Soligenix), RRx-001 (EpicentRx), MIT-001 (MitoImmune Therapeutics), and others. 

Soligenix's Dusquetide (SGX942) is an investigational innate defense regulator (IDR) intended to treat oral mucositis, particularly radiotherapy-induced oral mucositis (RIOM) in patients receiving treatment for head and neck cancer. The therapy works by regulating the innate immune system to alleviate inflammation, accelerate tissue repair, and lessen the severity and duration of mucosal damage without compromising the effectiveness of anticancer therapies. SGX942 is being investigated as a promising supportive care option that may enhance patients' quality of life, minimize treatment-related complications, and enable continuity of cancer therapy.

EpicentRx's RRx-001, an investigational small-molecule candidate, is under evaluation for the prevention and treatment of radiotherapy-induced oral mucositis in patients with head and neck cancer undergoing chemoradiotherapy. The therapy is designed to target oxidative stress, inflammation, and radiation-induced tissue damage to reduce both the severity and duration of oral mucositis. By selectively protecting healthy tissues while maintaining the tumor-killing efficacy of radiotherapy, RRx-001 has the potential to improve patient outcomes, support adherence to cancer treatment, and address a critical unmet need in supportive oncology care.

The anticipated launch of these emerging therapies are poised to transform the radiotherapy-induced oral mucositis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the radiotherapy-induced oral mucositis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about which pipeline drugs could transform radiotherapy-induced oral mucositis treatment @ Radiotherapy Induced Oral Mucositis Therapeutics Market

Radiotherapy Induced Oral Mucositis Epidemiology Segmentation

The radiotherapy-induced oral mucositis epidemiology section provides insights into the historical and current radiotherapy-induced oral mucositis patient pool and forecasted trends for the leading markets. In the United States, Grade III RIOM accounted for the highest number of cases in 2025, whereas Grade IV RIOM represented the lowest burden.

The radiotherapy-induced oral mucositis treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Cancer-specific Prevalent Cases Receiving Radiotherapy
• Cancer-specific Prevalent Cases of RIOM 
• Severity-specific  Prevalent Cases of RIOM
• Total Treated Cases of RIOM

Scope of the Radiotherapy Induced Oral Mucositis Market Report

• Radiotherapy Induced Oral Mucositis Patient Population Forecast
• Radiotherapy Induced Oral Mucositis Therapeutics Market Size
• Radiotherapy Induced Oral Mucositis Pipeline Analysis
• Radiotherapy Induced Oral Mucositis Market Size and Trends
• Radiotherapy Induced Oral Mucositis Market Opportunity
• Radiotherapy Induced Oral Mucositis Market Unmet Needs
• KOL's Views on Radiotherapy Induced Oral Mucositis
• Radiotherapy Induced Oral Mucositis Market Access and Reimbursement

Download the report to understand the top emerging radiotherapy-induced oral mucositis therapies @ Radiotherapy Induced Oral Mucositis Clinical Trials

Table of Contents

Related Reports

Radiotherapy Induced Oral Mucositis Clinical Trial Analysis

Radiotherapy Induced Oral Mucositis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RIOM companies, including Shanxi Zhendong Pharmacy Co Ltd, Solasia Pharma KK, Galera Therapeutics Inc., Bitop AG, UConn Health, Pfizer, Indena SpA, Innovation Pharmaceuticals Inc., Izun Pharma Ltd, and others.

Radiotherapy Induced Oral Mucositis in Head and Neck Cancer Market

Radiotherapy Induced Oral Mucositis in Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key RIOM in HNC companies, including AMAG Pharmaceuticals, SpePharm, Camurus, Innovation Pharmaceuticals, Enzychem Lifesciences Corporation, Galera Therapeutics, EpicentRx, Prothex Pharma, Soligenix, Onxeo, Monopar Therapeutics, Izun Pharmaceuticals, NeoMedLight, MuReva Phototherapy (Lumitex), BrainCool, and others.

Radiotherapy Induced Oral Mucositis in Prostate Cancer Market

Radiotherapy Induced Oral Mucositis in Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key RIOM in prostate cancer companies, including Novartis, Telix Pharmaceuticals, POINT Biopharma, Bayer, Curium, RayzeBio, Actinium Pharmaceuticals, Fusion Pharmaceuticals, Lantheus, Eli Lilly and Company (via its acquisition of Fusion Pharmaceuticals), Ratio Therapeutics, Orano Med, Alpha-9 Oncology, Blue Earth Therapeutics, and others.

Oral Mucositis Market

Oral Mucositis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key oral mucositis companies, including Amgen, Swedish Orphan Biovitrum, Access Pharmaceuticals, Chemo Mouthpiece, Aurora BioScience, Camurus, Innovation Pharmaceuticals, Enzychem Lifesciences Corporation, BrainCool, NeoMedLight, Monopar Therapeutics, MuReva (Lumitex), EpicentRx, Prothex Pharma, Soligenix, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us :
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com